Stephen Squinto, Gennao Bio chairman
Scoop: Stephen Squinto’s Yale spinout is raising a Series B for genetic medicines
The nucleic acid therapeutics at Stephen Squinto’s Yale-originated biotech are en route to a $40 million R&D payday.
After a Series A of that size …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
